t
Bioventix PLC announced that its Annual General Meeting was held on 04 December 2025. At this meeting, all resolutions put to shareholders were duly passed.
| Date | 4 Dec 2025 |
| Time | 15:59:47 |
| Category | AGMs and other meetings |
| ID | 3397K |
Bioventix PLC
("Bioventix" or the "Company")
Result of AGM
Bioventix PLC (AIM: BVXP) a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that at its Annual General Meeting held today, all resolutions put to shareholders were duly passed.
For further information please contact:
|
Bioventix plc |
|
Tel: 01252 728 001 |
|
Peter Harrison |
Chief Executive Officer |
|
|
|
|
|
|
Cavendish Capital Markets Limited |
Tel: 020 7220 0500 |
|
|
Geoff Nash/Elysia Bough |
Corporate Finance |
|
|
Nigel Birks/Harriet Ward |
ECM |
|
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.